{"paper_id":"5accd11a-3a33-46d0-b32b-f12c83f1fe50","body_text":"Literatur\nAmerican Fertility Society (1979) Classification of endometriosis. Fertil Steril 32:633\nCirkel U, Schweppe K-W, Ochs H, Schneider HPG (1986) Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience). In: Rolland R, Chadha DR, Willemsen WNP (eds) Gonadotropin Down-Regulation in Gynecological Practice. Alan R. Liss, New York, pp 189–199\nJänne O, Kauppila A, Kokko E, Lantto T, Rönnberg L, Vihko R (1981) Estrogen and progestin receptors in endometriotic lesions: Comparison with endometrial tissue. Am J Obstet Gynecol 141:562–566\nLemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41:863–871\nSchweppe K-W, Wynn RM, Beller FK (1984) Ultrastructural comparison of endometriotic implants and eutopic endometrium. Am J Obstet Gynecol 148:1024–1030\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nOchs, H., Cirkel, U., Schweppe, K.W. et al. Abhängigkeit zwischen ovarieller Suppression und Rückgang der Endometriose-Implantate bei LHRH-Analog(Buserelin)-Therapie. Arch Gynecol Obstet 245, 941–942 (1989). https://doi.org/10.1007/BF02417630\nIssue date:\nDOI: https://doi.org/10.1007/BF02417630","source_license":"CC0","license_restricted":false}